SCHEMBL2168383

SCHEMBL2168383

NC(=O)CCC(C(=O)O)N1C(=O)c2cccc(N)c2C1=O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.61
MEN1 O00255 3/20 0.61
ALDH1A1 P00352 4/20 0.58
KDM4E B2RXH2 4/20 0.58
POLB P06746 3/20 0.58
MAPK1 P28482 2/20 0.58
TP53 P04637 1/20 0.58
GLA P06280 1/20 0.58
CYP3A4 P08684 1/20 0.58
CYP2D6 P10635 1/20 0.58
HPGD P15428 1/20 0.58
ALOX12 P18054 1/20 0.58
NFKB1 P19838 1/20 0.58
APEX1 P27695 1/20 0.58
HSD17B10 Q99714 1/20 0.58
GAA P10253 2/20 0.47
TNF P01375 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.44
HSPA1A P0DMV8 1/20 0.41
PABPC1 P11940 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL672662 1.00 KMT2A (0.61) KMT2AMEN1ALDH1A1KDM4EPOLB
SCHEMBL29790446 1.00 KMT2A (0.61) KMT2AMEN1ALDH1A1KDM4EPOLB
SCHEMBL6261277 0.91 ALDH1A1 (0.72) KMT2AMEN1ALDH1A1KDM4EPOLB
SCHEMBL2167853 0.88 KMT2A (0.60) KMT2AMEN1ALDH1A1KDM4EPOLB
SCHEMBL25834661 0.88 KMT2A (0.60) KMT2AMEN1ALDH1A1KDM4EPOLB
SCHEMBL23702539 0.87 KMT2A (0.58) KMT2AMEN1ALDH1A1KDM4EPOLB
SCHEMBL17162091 0.87 KMT2A (0.58) KMT2AMEN1ALDH1A1KDM4EPOLB
SCHEMBL2169473 0.86 TNF (0.50) KMT2AMEN1ALDH1A1KDM4EPOLB
SCHEMBL6258804 0.86 KMT2A (0.57) KMT2AMEN1ALDH1A1KDM4EPOLB
SCHEMBL5025856 0.86 KMT2A (0.57) KMT2AMEN1ALDH1A1KDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4728487-B2 2011-07-20 JP claimed
EP-1163219-B1 SUBSTITUTED 1-OXO- AND 1,3-DIOXOISOINDOLINES AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS FOR REDUCING INFLAMMATORY CYTOKINE LEVELS CELGENE CORP (US) 2005-10-12 EP claimed
JP-2002539197-A 2002-11-19 JP claimed
US-6380239-B1 FOR THERAPY OF ARTHRITIS, RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, REPERFUSION INJURY, INFLAMMATORY BOWEL DISEASE, CROHN'S DISEASE, ULCERATIVE COLITIS, SYSTEMIC LUPUS ERYTHREMATOSIS, SCLERODERMA, APHTHOUS ULCERS, ASTHMA CELGENE CORPORATION 2002-04-30 US claimed
EP-1163219-A1 SUBSTITUTED 1-OXO- AND 1,3-DIOXOISOINDOLINES AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS FOR REDUCING INFLAMMATORY CYTOKINE LEVELS CELGENE CORPORATION (US) 2001-12-19 EP claimed
WO-2000055134-A1 SUBSTITUTED 1-OXO- AND 1,3-DIOXOISOINDOLINES AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS FOR REDUCING INFLAMMATORY CYTOKINE LEVELS CELGENE CORPORATION (US) 2000-09-21 WO claimed
CN-114907314-A Chemical synthesis method of pomalidomide 浙江工业大学 2022-08-16 CN disclosed
EP-1163219-B1 SUBSTITUTED 1-OXO- AND 1,3-DIOXOISOINDOLINES AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS FOR REDUCING INFLAMMATORY CYTOKINE LEVELS CELGENE CORP (US) 2005-10-12 EP disclosed
US-6380239-B1 FOR THERAPY OF ARTHRITIS, RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, REPERFUSION INJURY, INFLAMMATORY BOWEL DISEASE, CROHN'S DISEASE, ULCERATIVE COLITIS, SYSTEMIC LUPUS ERYTHREMATOSIS, SCLERODERMA, APHTHOUS ULCERS, ASTHMA CELGENE CORPORATION 2002-04-30 US disclosed
CN-1342146-A Substituted 1-oxo-and 1, 3-dioxoisoindolines and their use in pharmaceutical compositions for reducing inflammatory cytokine levels CELGENE CORP (US) 2002-03-27 CN disclosed
EP-1163219-A1 SUBSTITUTED 1-OXO- AND 1,3-DIOXOISOINDOLINES AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS FOR REDUCING INFLAMMATORY CYTOKINE LEVELS CELGENE CORPORATION (US) 2001-12-19 EP disclosed
WO-2000055134-A1 SUBSTITUTED 1-OXO- AND 1,3-DIOXOISOINDOLINES AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS FOR REDUCING INFLAMMATORY CYTOKINE LEVELS CELGENE CORPORATION (US) 2000-09-21 WO disclosed